•Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study
•From Dysbiosis to systemic health: Microbiome modulation as a unified therapeutic framework
•Modulation of experimental colitis by Enterococcus faecalis, Enterococcus faecium, and Bacillus subtilis: insights from infectious and chemical models
•Sarcopenia as a prognostic marker in inflammatory bowel disease: Implications for endoscopic outcomes and loss of response to biologic therapy-A systematic review with narrative synthesis
•The Burden of Viral Respiratory Infections in Immunosuppressed Inflammatory Bowel Disease Patients
